Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.60 |
| ▸ | TP53 | P04637 | 6/20 | 0.60 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | AHR | P35869 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13699889 | 0.92 | TP53 (0.60) | MAPTTP53MAPK10TSHRHSD17B10 | |
| SCHEMBL13699868 | 0.91 | MAPT (0.59) | MAPTTP53MAPK10TSHRHSD17B10 | |
| SCHEMBL4260304 | 0.89 | MAPT (0.55) | MAPTTP53MAPK10TSHRHSD17B10 | |
| SCHEMBL13699934 | 0.88 | MAPK10 (0.59) | MAPTTP53MAPK10TSHRHSD17B10 | |
| SCHEMBL13699858 | 0.88 | MAPT (0.64) | MAPTTP53MAPK10TSHRHSD17B10 | |
| SCHEMBL13699966 | 0.88 | MAPT (0.64) | MAPTTP53MAPK10TSHRHSD17B10 | |
| SCHEMBL13699726 | 0.85 | MAPT (0.53) | MAPTTP53MAPK10TSHRHSD17B10 | |
| SCHEMBL13699884 | 0.85 | MAPT (0.52) | MAPTTP53MAPK10TSHRHSD17B10 | |
| SCHEMBL13699763 | 0.84 | HPGD (0.67) | MAPTTP53MAPK10TSHRHSD17B10 | |
| SCHEMBL13699787 | 0.83 | HPGD (0.58) | MAPTTP53MAPK10TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239860-A1 | NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20090239860-A1 | NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239860-A1 | NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE | ADORA2A, ADORA2B, HTR1F | MAPT 4025/4885TP53 4721/4885MAPK10 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.